COPD drugs in China: Key market research findings
- The rise in healthcare expenditure in the country boosts the demand for COPD drugs
- The bronchodilators segment accounts for the majority share of the market’s revenue
- Key vendors – AstraZeneca, Boehringer Ingelheim, GSK, Merck, and Novartis
Technavio’s market research analysts predict the COPD drugs market in China to grow at a CAGR of around 17% between 2016 and 2020. The demand for chronic obstructive pulmonary disease (COPD) drugs in the region stems from the rise in healthcare expenditure. The guidelines released by the State Council in May 2014 indicate that there will be an increase in the spending in rural areas for clinics, insurance, equipment and drugs in comparison to urban areas, thus, triggering an increase in the uptake of COPD drugs.
The new market research report from Technavio presents a breakdown and analysis of the COPD drugs segments based on the drug class.
“Recently, there has been a substantial increase in the R&D investments made by several companies. The health challenges faced by countries in the emerging markets opens up ample opportunities for international pharma companies to concentrate more on R&D in this region. Besides, the initiatives taken by the Chinese government contribute to an increase in R&D, augmenting the overall drug development and growth in China,” says Barath Palada, Lead Analyst, Pharma, Technavio Research.
The bronchodilators segment will be the fastest growing segment of the COPD drugs market during the forecast period. These drugs are used for relaxing bronchial muscles to make the air passage through the lungs easy, resulting in normal breathing. Bronchodilators can be further classified into Beta-sympathomimetics, Anticholinergics, and Xanthine derivatives.
AstraZeneca, Boehringer Ingelheim, GSK, Merck, and Novartis are the key prominent vendors in the chronic obstructive pulmonary disease drugs market in China. Due to the presence of several small and large vendors, the COPD drugs market in China is highly competitive. The competitive environment is expected to intensify with the increase in product extensions, technological innovations, and an increase in the number of mergers and acquisitions.
A more detailed analysis is available in the Technavio report, COPD Drugs Market in China 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
